Join | Login







CanPKU+ Advocacy in Action

The Canadian Drug Access Playbook

A Milestone Guide for Advocates

Navigating the transition from clinical breakthrough to patient access in Canada is not a passive wait. It is a tactical exercise in navigating a fragmented and often opaque system.

This guide is designed as a strategic map for patients, caregivers and advocates. While the journey to public funding can take years, understanding what is happening at each milestone helps our community know where advocacy can have an impact, who makes the decisions, and what action to take next.

STAGE 1 - PURPLE -->
Stage 1

Health Canada Review The Safety & Efficacy Gatekeeper

The drug access journey begins at the federal level with a rigorous scientific evaluation.

This stage is the foundational gateway. Without Health Canada's authorization, a drug cannot legally be sold or reimbursed in Canada.

This phase is primarily regulatory and scientific. There are no formal windows for patient or caregiver input, so advocacy here is largely about preparing the community for the stages that follow.

The Milestone at a Glance
Health Canada assesses a new drug's safety, efficacy and quality and determines whether its clinical benefits outweigh its risks for the Canadian population.
What is happening behind the scenes?

The process begins when a manufacturer files a New Drug Submission (NDS).

Health Canada scientists review clinical trial data to determine whether the drug performs as claimed.

If successful, Health Canada may grant a Notice of Compliance (NOC) or a Notice of Compliance with Conditions (NOC/c).

An NOC/c can allow earlier access while the manufacturer continues to gather confirmatory evidence.

How long can this stage take?

Health Canada operates under defined performance targets. Standard reviews take longer, while a Priority Review may expedite the process to approximately 180 days.

If available evidence is not sufficient to resolve safety or efficacy concerns, a submission may not proceed to approval.

The Advocate's Toolkit: Enable Advocacy
  • Stay informed. Follow CanPKU+ updates to track treatments under review and anticipated Health Canada decisions.
  • Build your evidence base. Document the daily burden of your condition and limitations of current therapies.
  • Prepare your lived-experience story. The formal opportunity for patient input comes later, so this is the time to be ready.
What happens next?
Once Health Canada authorizes a drug for sale, the question changes from "Is it safe and effective?" to "Does it provide sufficient value?" as the treatment enters Health Technology Assessment.
↑ Back to top
Stage 2

Health Technology Assessment The Value Assessment

The Health Technology Assessment stage is one of the most important opportunities for patient advocacy.

This is where clinical effectiveness meets economic reality. Decision-makers assess whether a drug provides sufficient value compared with existing treatments. Evidence from patients and caregivers can help demonstrate the unmet need that clinical trials alone may not capture.

The Milestone at a Glance
Independent agencies assess clinical evidence and cost-effectiveness and make recommendations about whether a treatment should be publicly funded.
Who conducts the assessment?

Two primary organizations conduct Health Technology Assessments in Canada:

  • Canada's Drug Agency (CDA), formerly CADTH, for participating federal, provincial and territorial drug plans outside Quebec.
  • INESSS for Quebec.

Recommendations generally fall into three categories: Reimburse, Reimburse with conditions, or Do not reimburse.

How can patients participate?

CDA: Patient groups can submit evidence through the formal patient-input process. Individual patient submissions are not accepted.

INESSS: Both organizations and individual patients or caregivers can provide input.

The INESSS process asks submitters to conclude with five summary points so the central messages are clear.

What is Target Zero?

Through aligned reviews, HTA review can occur in parallel with Health Canada's regulatory review.

The goal of Target Zero is to eliminate unnecessary delay between Health Canada authorization and an HTA recommendation.

Once a draft recommendation is issued, advocates may have only a very short period to respond, including a potential 10-day feedback window.

The Advocate's Toolkit: Make Lived Experience Count
  • Contribute to patient input. Tell CanPKU+ how a treatment could affect work, school, energy, cognition, family life and quality of life.
  • Quebec residents: Take advantage of the opportunity to provide individual input to INESSS.
  • Review draft recommendations. Funding conditions need to reflect the realities of the people expected to meet them.
What happens next?
A positive value recommendation provides an important clinical and economic green light, but it does not automatically fund the medication. The process then moves to national pricing and negotiation.
↑ Back to top
STAGE 3 - BLUE <----- -->
Stage 3

National Pricing & pCPA Negotiations The Economic Table

This milestone focuses on the financial viability of bringing a treatment into Canada's public drug plans.

Much of this stage happens behind closed doors because negotiations are confidential. Even with a positive HTA recommendation, a treatment may remain inaccessible until pricing and coverage conditions are resolved.

The Milestone at a Glance
The PMPRB oversees maximum price considerations for patented medicines, while the pan-Canadian Pharmaceutical Alliance negotiates pricing and coverage conditions on behalf of participating public drug plans.
What does the PMPRB do?

The Patented Medicine Prices Review Board (PMPRB) works to ensure the prices of patented medicines sold in Canada are not excessive.

Its framework considers international price comparisons, including countries in the PMPRB11.

CanPKU+ spent six years participating in PMPRB guideline advocacy and consultations to ensure rare-disease perspectives were represented.

What does the pCPA do?

The pan-Canadian Pharmaceutical Alliance (pCPA) coordinates negotiations for participating public drug plans.

A successful negotiation may result in a Letter of Intent (LOI) between the pCPA and the manufacturer setting out agreed pricing and coverage conditions.

How long does negotiation take?

There are no fully transparent public timelines for this phase.

Processes such as the Early Negotiation Process are intended to explore ways of reducing delays for high-need treatments.

The Advocate's Toolkit: Keep the Pressure Constructive

Advocates are not sitting at the confidential negotiating table, but that does not mean advocacy stops.

Instead of:

"Why is this taking so long?"

Consider:

"How can our community support the data requirements or evidence of unmet need required to finalize this negotiation?"

Elected officials can also be reminded that a positive HTA recommendation cannot create patient access if negotiations do not move forward.

What happens next?
A national agreement creates a framework, not a mandate. Individual public drug plans still make their own listing decisions, which can lead to different access depending on where someone lives.
↑ Back to top
STAGE 4 - GREEN <----- -->
Stage 4

Public & Private Coverage Decisions The Postal Code & Private Plan Divide

This is where market access begins to become actual patient access.

Canada does not have one national drug plan. Coverage can depend on a province, territory, federal plan, private insurer or an employer's specific benefits design.

The Milestone at a Glance
Ministries of Health and public drug plans make final public listing decisions, while private coverage depends on both the insurer and the design selected by the plan sponsor.
How does public coverage work?

Provinces and other participating plans can negotiate Product Listing Agreements (PLAs) based on the national framework established through the pCPA process.

Individual jurisdictions may also have their own access pathways. Ontario, for example, has the Exceptional Access Program (EAP) for certain medications that are not available through the general formulary.

How does private coverage work?

Private drug coverage can involve two different decision-makers:

  • The insurer manages clinical adjudication and coverage rules.
  • The plan sponsor, often an employer or union, chooses the benefits design.

Two people can therefore have insurance administered by the same company while having very different medication coverage.

The Advocate's Toolkit: Triage Your Strategy

If the drug is not funded by your provincial public plan:
Your advocacy target may be the provincial Ministry of Health or responsible drug program.

If you have private insurance and the medication is "not a benefit":
Determine whether this is a clinical decision made by the insurer or a limitation in your employer or plan sponsor's benefits design.

Meeting Request Email Template
What happens next?
Being listed on a formulary does not always mean the medication is automatically approved for every patient. The final stage is navigating the individual claim, eligibility rules and possible authorization requirements.
↑ Back to top
STAGE 5 - ORANGE <----- -->
Stage 5

Implementation & Individual Access The Final Mile

Even after a positive funding decision, access may not be automatic.

This is the individual phase of the journey. A patient may still face eligibility criteria, prior authorization requirements or administrative barriers before a medication is actually dispensed.

The Milestone at a Glance
This stage involves the pharmacy-level experience, claims adjudication, prior authorization and, when necessary, the appeals process.
What can happen at the pharmacy?

When a pharmacist submits a claim using the medication's Drug Identification Number (DIN), the claim may require additional authorization.

A Prior Authorization process may require a clinician to provide evidence showing that the patient meets defined clinical criteria.

These criteria may include requirements related to previous therapies or other eligibility conditions.

What if there is still no coverage?

In some circumstances, patients may investigate Compassionate Access.

Compassionate access is voluntary and is generally provided by the manufacturer. It may sometimes act as a temporary bridge rather than a permanent coverage solution.

The Advocate's Toolkit: Appeal Strategically
  • Payer appeal: Focus on the clinical circumstances that make your situation different and explain why access to treatment is important.
  • Plan sponsor exception: When a benefits plan contains a financial limit or exclusion, it may be possible to ask the plan sponsor about an exception.
  • Use support networks: Patient Support Programs and CanPKU+ may be able to help identify information needed to support an appeal.
Privacy Matters

Asking an employer or union for an individual plan exception may require you to disclose information about your medical condition. Consider the potential benefit of the request alongside your personal privacy before deciding how to proceed.

The destination: access.
The journey from Health Canada review to the medicine cabinet can be long and complex. Persistent, informed and respectful advocacy helps communities move from approval toward meaningful access.
↑ Back to top
Advocacy in Action
Understand the milestone. Know who makes the decision. Take action where it matters.